Angiography for Mammaplasty

Phase-Based Progress Estimates
Angiography - Procedure
All Sexes
What conditions do you have?

Study Summary

This trial is testing whether using an imaging technique called pPCA will help doctors develop better surgical plans for patients with breast cancer undergoing post-mastectomy reconstruction surgery with free flap methods.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

5 Primary · 0 Secondary · Reporting Duration: At 2 years

At 2 years
Postoperative major complication rate
Year 2
Quality of life
Quality of life questionnaire (BREAST-Q)
Up to 2 years
Acceptance rate for pPCA-based surgical plans
Occurrence rate of surgical plan scenarios

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

Screening (pPCA)
1 of 1
Experimental Treatment

138 Total Participants · 1 Treatment Group

Primary Treatment: Angiography · No Placebo Group · N/A

Screening (pPCA)Experimental Group · 3 Interventions: Angiography, Quality-of-Life Assessment, MRI-Based Angiogram · Intervention Types: Procedure, Other, Procedure
First Studied
Drug Approval Stage
How many patients have taken this drug
MRI-Based Angiogram

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: at 2 years

Who is running the clinical trial?

Ohio State University Comprehensive Cancer CenterLead Sponsor
284 Previous Clinical Trials
285,727 Total Patients Enrolled
Michael Knopp, MDPrincipal InvestigatorOhio State University Comprehensive Cancer Center
1 Previous Clinical Trials
280 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are scheduled to receive breast reconstruction using one of the abdominal-based free flap techniques (DIEP flap, SIEA flap, or TRAM flap) within the next 12 months.
You are scheduled to receive a preoperative CTA prior to surgery.
You are able to lie in both prone and supine positions for at least 30 minutes.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 26th, 2021

Last Reviewed: October 29th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.